Trends and factors associated with influenza vaccination in subjects with asthma: analysis of the Korea National Health and Nutrition Examination Survey between 2010 and 2019

Sang Hyuk Kim^{*}, Hye Yun Park^{*}, Hwasik Jung, Sungmin Zo, Saerom Kim, Dong Won Park, Tai Sun Park, Ji-Yong Moon, Sang-Heon Kim¹, Tae-Hyung Kim, Jang Won Sohn, Ho Joo Yoon, Hyun Lee⁺ and Sun Hye Shin⁺

Abstract

Background: Despite the importance of influenza vaccination, its rates in subjects with asthma are suboptimal, especially in the young population.

Methods: Among 72,843 adults aged ≥18 years from the Korea National Health and Nutrition Examination Survey conducted between 2010 and 2019, 1643 with asthma were included. The yearly trends and factors associated with influenza vaccination were analyzed in subjects with asthma. In addition, stratified analyses were performed by age group ($<65 \text{ versus} \ge 65 \text{ years}$). **Results:** During the study period, the overall influenza vaccination rate among subjects with asthma fluctuated from 51.0% to 64.3%, with a consistently higher vaccination rate in elderly subjects than in young subjects. Among young subjects with asthma, factors positively associated with influenza vaccination were female sex [adjusted odds ratio (aOR)=1.66, 95% confidence interval (CI) = 1.11-2.49], current asthma being treated (aOR = 1.69, 95% CI = 1.14-2.50), history of pulmonary tuberculosis (aOR = 2.01, 95% CI = 1.04-3.87), and dyslipidemia (aOR = 1.86, 95% CI = 1.05-3.30). However, unmarried subjects showed an inverse relationship (aOR=0.50, 95% CI=0.34-0.75). In elderly subjects, unmarried status (aOR=0.52, 95% CI = 0.29 - 0.94), being underweight (aOR = 0.29, 95% CI = 0.09 - 0.97), and having a low income (aOR = 0.42, 95% CI = 0.18-0.97) were factors negatively associated with influenza vaccination. **Conclusion:** In the last 10 years, influenza vaccination rates have still been insufficient in subjects with asthma, particularly in young subjects. Considering the factors that are influencing the vaccination rates of young subjects, public policies to increase influenza vaccination rates in subjects with asthma need to be established urgently.

Keywords: asthma, epidemiology, influenza, prevalence, vaccination

Received: 24 April 2022; revised manuscript accepted: 18 August 2022.

Introduction

Asthma is a common inflammatory disorder of the airways characterized by airway hyperresponsiveness.¹ Acute exacerbation of asthma is an important factor associated with increased health care needs, including emergency department visits and hospital admissions.^{2,3} As a virulent respiratory virus, influenza is one of the common triggers for acute exacerbation of asthma.⁴ Subjects with asthma are more susceptible to influenza infection due to impaired antiviral immunity.^{5,6} Consequently, asthmatics are at increased risk of acute exacerbation, often leading to hospitalization, attributable to influenza infection.^{7,8}

Although there are antiviral treatments for influenza infection, vaccination is the most effective

Ther Adv Chronic Dis

2022, Vol. 13: 1–12

DOI: 10.1177/ 20406223221123979

© The Author(s), 2022. Article reuse guidelines: sagepub.com/journalspermissions

Correspondence to: Hyun Lee

Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, 222, Wangsimniro Seongdong-gu, Seoul 04763, Korea. namuhanayeyolahanyang. ac.kr

Sun Hye Shin

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Korea. **freshsun@g.skku.edu**

Sang Hyuk Kim

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea

Hye Yun Park Hwasik Jung Sungmin Zo Saerom Kim

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Dong Won Park Tai Sun Park Ji-Yong Moon Sang-Heon Kim Tae-Hyung Kim Jang Won Sohn Ho Joo Yoon

Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

*Sang Hyuk Kim and Hye Yun Park contributed equally to this work.

[†]Hyun Lee and Sun Hye Shin contributed equally to this work.

journals.sagepub.com/home/taj



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

strategy for coping with influenza.9 The effectiveness of vaccination has been demonstrated in subjects with asthma, which prevented nearly half of influenza infections and approximately 60-80% of asthma attacks.^{10,11} Accordingly, guidelines have recommended that subjects with asthma should be vaccinated against the influenza virus every year.¹²⁻¹⁴ However, the previous literature has consistently reported a suboptimal rate of influenza vaccination in this population.^{15–19} A study using Korean national data reported that the influenza vaccination rate for the general population more than 40 years of age was 45.2%, while it was 76.8% for those aged 65 years and older.²⁰ In patients with asthma, the influenza vaccination rate for those aged 65 years and older was higher at 81.5%, but the vaccination rate below 50 years of age was only 28.3%.18 In addition, several factors have been suggested to be associated with low influenza vaccination rates, with young age contributing as a significant factor.^{16-18,21} Consequently, various methods, such as social marketing, were proposed to increase influenza vaccination rates in young subjects.²²

However, despite these efforts, there are no recent data on whether influenza vaccination rates have increased in subjects with asthma and whether younger age is no longer associated with the low influenza vaccination rates. Therefore, we aimed to investigate the recent yearly trends of influenza vaccination rates and the factors associated with influenza vaccination in subjects with asthma, with a focus on age.

Materials and methods

Study population and design

The Korea National Health and Nutrition Examination Survey (KNHANES) is a population-based nationwide survey that assesses the health and nutritional status of the non-institutionalized Korean population. The survey was conducted by the Korea Disease Control and Prevention Agency (KDCA). The study population was selected using a stratified multistage probability cluster sampling method. More detailed information on the KNHANES has been provided in a previous study.²³

We used data from the KNHANES V (2010–2012), VI (2014–2015), VII (2016–2018), and VIII (2019). In this study, data from the

KNHANES 2013 were not included because the influenza vaccination data were not available to the public. A total of 93,338 subjects were included in the surveys over 9 years, and 72,843 agreed to participate (participation rate, 78.0%). Of the 72,843 participants, we excluded subjects aged <18 years (n=14,659) or those who had missing data for influenza vaccination (n=6,004). Of the remaining 52,180 subjects, we excluded 50,537 who did not have a history of physician-diagnosed asthma. Finally, 1,643 subjects with asthma were included in the analysis (Figure 1).

Outcomes

The outcomes were as follows: (1) influenza vaccination rate over the study period and (2) factors associated with influenza vaccination in subjects with asthma. Subject's history of influenza vaccination was investigated using the following question: 'Have you ever been vaccinated against influenza in the past year?'

Exposure

Subjects with asthma were defined as those with a history of physician-diagnosed asthma. Physician-diagnosed asthma was assessed by the question, 'Have you ever been diagnosed with asthma by a doctor?' For stratified analyses, subjects with asthma were further subdivided into (1) young subjects (age < 65 years) and (2) elderly subjects (age ≥ 65 years).

Measurements and other definitions

Body mass index (BMI) was calculated by dividing an individual's weight by the square of their height (kg/m²). Past smoking was defined as a person who smoked five or more cigarettes in their lifetime but who does not currently smoke. Single, separated, divorced, and widowed individuals were defined as unmarried. Monthly household income was defined as low for the lowest quartile, intermediate for the second to third quartiles, and high for the highest quartile. Regular walking was defined as walking at least five times a week for more than 30 min at a time. Chronic cough was defined as a cough symptom lasting 3 months or longer. Chronic sputum was defined as sputum accompanied by coughing for more than 3 months per year. Physical limitation was defined using the question, 'Do you have limitations in your daily life?' Hypertension was defined as a systolic blood




Figure 1. Flow chart of the study population.

pressure \geq 140 mmHg, diastolic blood pressure \geq 90 mmHg, or treatment with antihypertensive medication. Dyslipidemia was defined as lowdensity lipoprotein cholesterol level greater than 130 mg/dl, high-density lipoprotein cholesterol level less than 40 mg/dl, or treatment with lipidlowering medications. Diabetes mellitus was defined as a fasting plasma glucose level of \geq 126 mg/dl or treatment with glucose-lowering medications. Other comorbidities were defined on the basis of a physician's diagnosis.²⁴

Statistical analysis

Data are expressed as weighted percentages with standard errors. The p values for differences according to influenza vaccination history were calculated using Pearson's chi-square test. Logistic regression analysis was performed to explore factors associated with influenza vaccination in subjects with asthma. In multivariable analysis, demographic profiles (age, sex, and BMI), personal habits (smoking status and regular walking), socioeconomic factors (marital status, income, and education), symptoms (any respiratory symptoms and physical limitation), asthma status (no asthma at present, not being treated for asthma, and currently being treated for asthma), and comorbidities were included. Income is included in the adjustment because subjects with asthma have to pay for influenza

vaccination, whereas it is free for the elderly $(\geq 65 \text{ years})$ in Korea.

The sampling weights were adjusted for all analyses using the 'survey' package of R. Participants in the single primary survey unit stratum were centered at the sampled grand mean. Missing values were handled using the missing indicator method, which analyzes missing values by grouping them into missing categories. Statistical significance was defined as a two-sided p value of less than 0.05. All analyses were performed using R version 4.0.3 (R Core Team 2021; R Foundation for Statistical Computing, Vienna, Austria).

Results

Baseline characteristics

The baseline characteristics of the subjects with asthma are shown in Table 1. Among subjects with asthma, compared with unvaccinated subjects, those vaccinated against influenza were more likely to be older (58.1% versus 11.5%, p < 0.001) and female (67.5% versus 55.5%, p < 0.001). Vaccinated subjects were less likely to be current smokers (11.4% versus 24.2%, p < 0.001), unmarried (35.5% versus 48.6%, p < 0.001), college graduates (16.3% versus 34.4%, p < 0.001), and regular walker (33.7%

THERAPEUTIC ADVANCES in Chronic Disease

Table 1. Baseline characteristics of the study population.

	Total (<i>n</i> = 1,643)	Unvaccinated (<i>n</i> =695)	Vaccinated (<i>n</i> =948)	<i>p</i> value
Age (years)				<0.001
18-64	61.8 (1.4)	88.5 (1.3)	41.9 (1.9)	
≥65	38.2 (1.4)	11.5 (1.3)	58.1 (1.9)	
Sex				< 0.001
Male	37.7 (1.3)	44.5 (2.1)	32.6 (1.6)	
Female	62.4 (1.3)	55.5 (2.1)	67.5 (1.6)	
BMI, kg/m²				0.096
Underweight (<18.5)	4.7 (1.3)	6.2 (1.1)	3.6 (0.7)	
Normal weight (18.5–24.9)	57.6 (0.6)	57.7 (1.9)	57.6 (1.8)	
Overweight/obese (≥25)	37.2 (1.3)	35.5 (1.9)	38.5 (1.8)	
Smoking status				< 0.001
Non-smoker	62.7 (1.3)	61.0 (2.0)	64.0 (1.7)	
Past smoker	19.5 (1.1)	14.1 (1.4)	23.6 (1.6)	
Current smoker	16.9 (1.1)	24.2 (1.8)	11.4 (1.2)	
Marital status				< 0.001
Unmarried	41.1 (1.3)	48.6 (2.1)	35.5 (1.8)	
Married	58.9 (1.3)	51.4 (2.1)	64.6 (1.8)	
Income				0.956
Low	29.2 (1.3)	29.2 (2.0)	29.2 (1.6)	
Intermediate	48.3 (1.4)	48.7 (2.0)	48.1 (1.8)	
High	22.1 (1.2)	21.6 (1.6)	22.4 (1.5)	
Education				< 0.001
Elementary school graduate	36.0 (1.4)	16.4 (1.6)	50.7 (1.8)	
Middle/high school graduate	39.0 (1.3)	48.9 (2.2)	31.7 (1.7)	
College graduate	24.1 (1.2)	34.4 (2.0)	16.3 (1.3)	
Regular walking	36.9 (1.4)	41.0 (2.1)	33.7 (1.7)	0.014
Symptoms				
Any respiratory symptoms	14.9 (1.0)	9.6 (1.2)	18.8 (1.4)	< 0.001
Cough	9.9 (0.8)	7.0 (1.1)	12.0 (1.2)	< 0.001
Sputum	12.3 (0.9)	7.9 (1.1)	15.7 (1.3)	< 0.001

(Continued)

Volume 13

Table 1. (Continued)

	Total (<i>n</i> = 1,643)	Unvaccinated (<i>n</i> = 695)	Vaccinated (<i>n</i> = 948)	p value		
Physical limitations	20.2 (1.1)	12.9 (1.5)	25.7 (1.5)	< 0.001		
Asthma status				< 0.001		
No asthma at present	42.0 (1.4)	54.4 (2.0)	32.7 (1.7)			
Not being treated for asthma	22.7 (1.1)	24.1 (1.8)	21.6 (1.5)			
Currently being treated for asthma	35.3 (1.3)	21.5 (1.8)	45.7 (1.8)			
Comorbidities						
Pulmonary tuberculosis	9.0 (0.8)	4.6 (0.9)	12.3 (1.2)	< 0.001		
Hypertension	39.2 (1.4)	22.6 (1.8)	51.7 (1.8)	< 0.001		
Diabetes mellitus	13.9 (0.9)	8.5 (1.2)	18.0 (1.4)	< 0.001		
Dyslipidemia	34.3 (1.3)	26.3 (1.9)	40.4 (1.8)	< 0.001		
Allergy						
Atopic dermatitis	8.5 (0.8)	13.3 (1.4)	4.9 (0.8)	< 0.001		
Allergic rhinitis	19.5 (1.1)	26.0 (1.7)	14.7 (1.3)	< 0.001		
Cardiovascular disease	5.4 (0.7)	3.3 (0.8)	7.0 (0.9)	0.002		

versus 41.0%, p=0.014), but had more respiratory symptoms (18.8% *versus* 9.6%, p<0.001) and physical limitations (25.7% *versus* 12.9%, p<0.001) and were more likely being treated for asthma (45.7% *versus* 21.5%, p<0.001). However, there were no differences in BMI and income between the two groups.

Regarding comorbidities, compared to unvaccinated subjects, vaccinated subjects had more history of pulmonary tuberculosis (12.3% versus 4.6%, p < 0.001), hypertension (51.7% versus 22.6%, p < 0.001), diabetes mellitus (18.0% versus 8.5%, p < 0.001), dyslipidemia (40.4% versus 26.3%, p < 0.001), and cardiovascular disease (7.0% versus 3.3%, p = 0.002), but less atopic dermatitis (4.9% versus 13.3%, p < 0.001) and allergic rhinitis (14.7% versus 26.0%, p < 0.001).

Influenza vaccination rates and yearly trends

The overall influenza vaccination rates were 57.2% for all subjects with asthma, 38.7% for young subjects with asthma, and 87.1% for

elderly subjects with asthma. The annual trends in influenza vaccination are shown in Figure 2. More than 10 years, the vaccination rate fluctuated in subjects with asthma, ranging from 51.0% to 64.3%. In younger subjects with asthma, the vaccination rate increased from 36.3% in 2010 to 46.6% in 2014 and then sharply decreased in 2015. This dropped vaccination rate was maintained until 2017 and started to increase in 2018. In elderly subjects with asthma, small fluctuations in vaccination rates were observed between 2010 and 2012, ranging from 80.0% to 88.1%. Thereafter, the vaccination rate increased steadily from 86.8% in 2014 and peaked in 2019 (92.6%).

Factors associated with influenza vaccination

Supplemental Table S1 and Table 2 show univariable and multivariable logistic regression analyses of influenza vaccination in the subjects with asthma, resprectively. In multivariable analysis, age was the factor most strongly associated with influenza vaccination [adjusted odds ratio

THERAPEUTIC ADVANCES in Chronic Disease




Figure 2. Influenza vaccination trends in subjects with asthma between 2010 and 2019.

(aOR) = 6.49, 95% CI (confidence interval) = 4.35–9.67 for ≥65 years]. Other identified factors showing an association with influenza vaccination were female sex (aOR=1.72, 95% CI=1.21–2.44), unmarried state (aOR=0.51, 95% CI=0.37–0.71), current asthma being treated (aOR=1.82, 95% CI=1.32–2.51), hypertension (aOR=1.47, 95% CI=1.07–2.01), and dyslipidemia (aOR=1.75, 95% CI=1.07–2.85).

In the stratified analysis, young subjects with asthma, who are female (aOR=1.66, 95% CI=1.11-2.49), receiving current asthma treatment (aOR=1.69, 95% CI=1.14-2.50), and with a history of pulmonary tuberculosis (aOR=2.01, 95% CI=1.04-3.87) or dyslipidemia (aOR=1.86, 95% CI=1.05-3.30) were positively associated with influenza vaccination, whereas those with an unmarried status were negatively associated (aOR=0.50, 95% CI=0.34-0.75). Among elderly subjects with asthma, those who were underweight (aOR=0.29,95% CI=0.09-0.97), unmarried (aOR=0.52, 95%) CI=0.29-0.94), and had a low income (aOR = 0.42, 95% CI = 0.18 - 0.97) were less likely to be vaccinated against influenza.

Discussion

This study comprehensively investigated trends of and factors associated with influenza vaccination rate in subjects with asthma using recent nationwide population-based data of Korea. In the analysis of the trend between 2010 and 2019, the influenza vaccination rate among subjects with asthma has fluctuated at a suboptimal level without a significant increase. In addition, our results showed that lower influenza vaccination rate in subjects with asthma is mostly attributable to young subjects and revealed several important factors associated with vaccination uptake.

Previous studies from western countries have shown the low influenza vaccination rate in subjects with asthma. According to the 2007 Behavioral Risk Factor Surveillance System in the United States, influenza vaccination coverage was 39.9% for adult asthmatics (≥ 16 years of age).¹⁵ Influenza vaccination rates in European countries (≥ 16 years of age) were 38.0% in the Spanish National Health Study 200617 and 35.2% in the European Health Survey 2009,¹⁶ which is comparable to that in the United States. In Korea, the influenza vaccination rate was 61.1% for adults with asthma from 2010 Korean Community Health Survey (≥ 19 years of age).¹⁸ However, in another recent Korean study using 2017 Korea Youth Risk Behavior Web-Based Survey, the influenza vaccination rate was 41.8% in Korean adolescents (13-18 years of age) with asthma.19

Total subjects (n = 1643) Young subjects with asthma Elderly subjects with asthma (n=999) (n = 644)aOR (95% CI) aOR (95% CI) aOR (95% CI) p value p value p value Age (years) 18-64 Ref. 6.49 (4.35-9.67) ≥65 < 0.001 Sex Male Ref. Ref. Ref. Female 1.72 (1.21-2.44) 0.002 1.66(1.11 - 2.49)0.014 1.73 (0.75-4.03) 0.201 BMI (kg/m²) 0.77(0.36 - 1.65)0.507 1.10(0.56-2.17)0.781 Underweight 0.044 0.29 (0.09-0.97) Normal Ref. Ref. Ref. Overweight or 0.90(0.68 - 1.20)0.478 0.86(0.61 - 1.20)0.370 0.92(0.50-1.69)0.795 obese Smoking status Non-smoker Ref. Ref. Ref. Past smoker 1.26 (0.85-1.86) 0.252 1.14(0.71 - 1.84)0.589 1.75 (0.78-3.95) 0.174 0.093 0.235 0.419 Current smoker 0.69 (0.45-1.06) 0.75 (0.46-1.21) 0.68 (0.26-1.75) Marital status Unmarried 0.51 (0.37-0.71) 0.50(0.34 - 0.75)0.52(0.29 - 0.94)0.030 < 0.001 < 0.001 Ref. Married Ref. Ref. Income 0.536 0.545 0.42(0.18 - 0.97)0.042 Low 0.88(0.59 - 1.31)1.14 (0.74–1.77) Intermediate 0.79(0.59 - 1.08)0.138 0.80(0.56 - 1.13)0.202 0.76(0.34 - 1.71)0.510 High Ref. Ref. Ref. Education Elementary school Ref. Ref. Ref. graduate Middle/high school 0.72 (0.48-1.08) 0.114 0.66 (0.38-1.12) 0.125 0.88(0.42 - 1.86)0.736 graduate 0.65 (0.41-1.03) 0.068 0.64 (0.36-1.12) 0.115 0.54(0.15 - 1.99)0.352 College graduate Regular walking 0.93 (0.71-1.22) 0.617 0.79 (0.57-1.08) 0.140 1.76 (0.90-3.42) 0.098 Any respiratory 1.11 (0.76-1.63) 0.588 1.22 (0.76-1.96) 0.407 0.93 (0.49-1.80) 0.837 symptoms

Table 2. Factors associated with influenza vaccination in subjects with asthma.

(Continued)

THERAPEUTIC ADVANCES in Chronic Disease

Table 2. (Continued)

	Total subjects (<i>n</i> = 1643)		Young subjects with asthma (n = 999)		Elderly subjects with asthma (n=644)	
	aOR (95% CI)	p value	aOR (95% CI)	p value	aOR (95% CI)	p value
Asthma status						
No current asthma	Ref.		Ref.		Ref.	-
Current asthma being untreated	0.93 (0.65–1.32)	0.672	0.87 (0.58–1.31)	0.499	0.99 (0.45-2.14)	0.972
Current asthma being treated	1.82 (1.32–2.51)	<0.001	1.69 (1.14–2.50)	0.009	1.80 (0.93–3.50)	0.081
Physical limitations	1.11 (0.77–1.58)	0.577	1.08 (0.68–1.71)	0.743	1.26 (0.64–2.49)	0.506
Comorbidities						
Pulmonary tuberculosis	1.55 (0.92–2.63)	0.100	2.01 (1.04–3.87)	0.037	1.01 (0.47–2.13)	0.987
Hypertension	1.47 (1.07–2.01)	0.018	1.34 (0.90–1.98)	0.151	1.70 (0.92–3.14)	0.092
Diabetes mellitus	1.03 (0.64–1.66)	0.912	1.23 (0.62–2.42)	0.548	0.89 (0.42–1.91)	0.767
Dyslipidemia	1.75 (1.07–2.85)	0.026	1.86 (1.05–3.30)	0.035	1.20 (0.35–4.14)	0.770
Allergy						
Atopic dermatitis	0.77 (0.45–1.34)	0.355	0.86 (0.48–1.53)	0.605	0.61 (0.15-2.46)	0.486
Allergic rhinitis	0.92 (0.61–1.37)	0.669	0.99 (0.62–1.56)	0.954	0.73 (0.28–1.92)	0.522
Cardiovascular disease	0.77 (0.40–1.48)	0.433	0.73 (0.24–2.23)	0.585	0.74 (0.29–1.86)	0.518

Bold font indicates statistical significance.

After the 2009 influenza pandemic, only a few studies have investigated the influenza vaccination rates in subjects with asthma,^{18,19} and studies that have evaluated the long-term trend of influenza vaccination are even scarcer. Previously, World Health Assembly recommended increasing influenza vaccination coverage up to at least 75% in subjects with underlying diseases. Surprisingly, contrary to expectations, the influenza vaccination rate in subjects with asthma remains suboptimal and has not increased over the last decade. This suggests that despite national and international asthma guidelines emphasizing the importance of influenza vaccination for asthmatics,^{12,13} the current vaccination strategies are insufficient to encourage them to be vaccinated. Moreover, given that coinfection with SARS-CoV-2 and influenza

virus was associated with a higher risk of poor outcomes,^{26,27} it would be important to re-evaluate whether influenza vaccination for asthma is adequately implemented in each country.

Many factors are associated with influenza vaccination rates in subjects with asthma, and a wellknown factor is age.^{16–18,21,28} In a pooled analysis of a national population-based survey of Canada, Guthrie *et al.*²⁹ reported the rate of 'feeling that influenza vaccine was unnecessary' was 1.6-fold higher in adult asthmatics aged 18–24 years than those aged 55–64 years. Our study showed that only 38% of young subjects with asthma were vaccinated, whereas almost 90% of elderly subjects with asthma were vaccinated. First, this large difference may be explained by public policies.

The Korean government expanded the coverage for free influenza vaccination from 2005 to include elderly subjects (aged \ge 65 years),³⁰ which might have contributed to the results of our study. Second, it is known that many young adults are hesitant to be vaccinated against various diseases, including influenza.³¹ The suggested reasons are unawareness of vaccination recommendations, mistrust of vaccination effects, and confidence in their health.^{17,28} Whether influenza infection in young subjects with asthma who had infrequent asthma symptoms is associated with severe outcomes remains unclear. However, it is well known that subjects with mild asthma are still at risk of severe asthma exacerbation,32 and exposure to viruses that might trigger this is unpredictable. Thus, clinicians should evaluate the influenza vaccination status of young subjects with asthma and make greater efforts to vaccinate them against influenza.

In line with the previous studies in asthmatics,15,18,33 we found increased adherence to influenza vaccination in women and in subjects who were married. In addition, subjects who received asthma treatment and had a history of pulmonary tuberculosis and dyslipidemia were more likely to be vaccinated against influenza. It seems natural that subjects who have been treated in the past or are currently receiving treatment for respiratory diseases, such as asthma and pulmonary tuberculosis, are more prone to influenza vaccination.¹⁶ Subjects with chronic diseases, such as diabetes and dyslipidemia, might have higher chances to interact with health care providers than those without chronic diseases. Moreover, physicians will probably pay more attention to influenza prevention in their patients. This is because patients with chronic diseases may be at a higher risk of serious influenza-related outcomes if they also have asthma.34 These circumstances may lead to increased vaccination uptake. However, the exact social or biological mechanism of these factors leading to influenza vaccination remains an issue warranting future studies.

Moreover, being underweight, being unmarried, and having a low income were found to be related to decreased influenza vaccination rates among elderly subjects with asthma. The benefits from vaccination might be greater in this population, as these are known to be associated with various health issues.^{35–37} Nevertheless, misbeliefs caused by a lack of information, such as concerns about vaccine side effects, may prevent this population from becoming vaccinated.²⁸ Although the overall influenza vaccination rate is sufficient in elderly subjects with asthma, it is necessary to examine whether there are other underprivileged populations within the elderly.

The strength of this study is that recent influenza vaccination rates among subjects with asthma were analyzed using nationally representative survey data. Through a 10-year trend analysis, our study found that the asthma guidelines' recommendations for influenza vaccination are not followed in the real world. Nonetheless, very few studies have reported influenza vaccination trends among asthmatic subjects after the 2009 influenza pandemic. Therefore, similar studies need to be conducted in each country to investigate and improve the national influenza vaccination rates in subjects with asthma. Another strength is that comprehensive factors were included to evaluate their association with influenza vaccination, which can help identify subgroups of subjects with asthma in whom to encourage vaccination. However, our study had some limitations. First, the causal relationship identified was uncertain because our study was conducted using cross-sectional data. Second, recall bias was possible because a history of asthma and influenza vaccination was assessed using a questionnaire. Third, common barriers to influenza vaccination among asthmatics, such as support for vaccination and worries about being sick after vaccination,²⁸ were not investigated in this study. Fourth, although we included the variable of current treatment status (being treated versus untreated) in the analysis, we could not include detailed information on treatment, such as asthma duration or treatment steps, because these data were not available in the KNHANES dataset. Fifth, in some categories, such as underweight elderly subjects, the number of subjects was relatively small. Findings in these categories require cautious interpretation. Finally, the uniqueness of the Korean medical system should be considered when interpreting the results because Korea implements the National Health Insurance System. Therefore, generalizations to other countries must be carefully made.

In conclusion, influenza vaccination rates have been insufficient in subjects with asthma in the last 10 years. The influenza vaccination rate was consistently lower in young subjects with asthma than that in the elderly. In young subjects with asthma, female sex, current asthma treatment, history of pulmonary tuberculosis, and dyslipidemia were positively associated with influenza vaccination, whereas an unmarried status was negatively associated. Public policies to increase influenza vaccination rates in subjects with asthma, considering the factors that are influencing the vaccination rates of young subjects, urgently need to be established.

Declarations

Ethics approval and consent to participate

We conducted this study following the Declaration of Helsinki. The Institutional Review Board (IRB) of the KDCA approved the study (IRB: 2010-02CON-21-C, 2011-02CON-06-C, 2012-01EXP-01-2C, 2013-12EXP-03-5C, 2018-01-03-P-A, and 2018-01-03-C-A). Written informed consent was obtained from all participants, and anonymized data were provided.

Consent for publication

Not applicable.

Author contributions

Sang Hyuk Kim: Data curation; Formal analysis; Visualization; Writing – original draft.

Hye Yun Park: Writing - original draft.

Hwasik Jung: Writing - review & editing.

Sungmin Zo: Writing – review & editing.

Saerom Kim: Writing - review & editing.

Dong Won Park: Writing - review & editing.

Tai Sun Park: Writing – review & editing.

Ji-Yong Moon: Writing - review & editing.

Sang-Heon Kim: Writing – review & editing.

Tae-Hyung Kim: Writing – review & editing.

Jang Won Sohn: Writing – review & editing.

Ho Joo Yoon: Writing – review & editing.

Hyun Lee: Conceptualization; Supervision; Validation; Writing – original draft.

Sun Hye Shin: Supervision; Validation; Writing – original draft.

Acknowledgements

There are no acknowledgements to declare.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

Raw data of this study are publicly available in Korea Disease Control and Prevention Agency database (https://knhanes.kdca.go.kr/knhanes/ sub03/sub03_02_05.do).

ORCID iDs

Sang Hyuk Kim D 0002-0410-8524	https://orcid.org/0000-
Sang-Heon Kim 🕩 0001-8398-4444	https://orcid.org/0000-
Hyun Lee D https 1269-0913	://orcid.org/0000-0002-
Sun Hye Shin D https 3164-889X	://orcid.org/0000-0003-

Supplemental material

Supplemental material for this article is available online.

References

- 1. Huang K, Yang T, Xu J, *et al.* Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. *Lancet* 2019; 394: 407–418.
- Ekström M, Nwaru BI, Wiklund F, et al. Risk of rehospitalization and death in patients hospitalized due to asthma. J Allergy Clin Immunol Pract 2021; 9: 1960–1968.
- Zein JG, Wu CP, Attaway AH, et al. Novel machine learning can predict acute asthma exacerbation. *Chest* 2021; 159: 1747– 1757.
- 4. Veerapandian R, Snyder JD and Samarasinghe AE. Influenza in asthmatics: for better or for worse? *Front Immunol* 2018; 9: 1843–1843.

- Wark PAB. Why are people with asthma more susceptible to influenza. *Eur Respir J* 2019; 54: 1901748.
- Wu Q, Jiang D, Smith S, *et al.* IL-13 dampens human airway epithelial innate immunity through induction of IL-1 receptor-associated kinase M. *J Allergy Clin Immunol* 2012; 129: 825–833.
- Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbation—a GA2 LEN-DARE systematic review. Allergy 2011; 66(4)458–468.
- Trinh P, Jung TH, Keene D, *et al.* Temporal and spatial associations between influenza and asthma hospitalisations in New York City from 2002 to 2012: a longitudinal ecological study. *BMJ Open* 2018; 8: e020362.
- 9. Brody H. Influenza. Nature 2019; 573: S49.
- Martínez-Baz I, Navascués A, Casado I, *et al.* Effect of influenza vaccination in patients with asthma. *CMAJ* 2021; 193: E1120–E1128.
- Vasileiou E, Sheikh A, Butler C, *et al.* Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. *Clin Infect Dis* 2017; 65: 1388–1395.
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, https://ginasthma.org/wp-content/ uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed 29 July 2022).
- 13. The Korean Academy of Tuberculosis and Respiratory Disease. Korean guideline for asthma: Updated 2020, https://lungkorea.org/ bbs/?code=guide (accessed 29 July 2022).
- British guideline on the management of asthma. *Thorax* 2008; 63(Suppl. 4): iv, 1–121.
- Lu PJ, Euler GL and Callahan DB. Influenza vaccination among adults with asthma findings from the 2007 BRFSS survey. *Am J Prev Med* 2009; 37: 109–115.
- Santos-Sancho JM, López-de Andrés A, Jimenez-Trujillo I, *et al.* Adherence and factors associated with influenza vaccination among subjects with asthma in Spain. *Infection* 2013; 41: 465–471.
- Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, *et al.* Coverage and predictors of adherence to influenza vaccination among Spanish children and adults with asthma. *Infection* 2010; 38: 52–57.
- Chung JH, Kim TH and Han CH. Factors influencing influenza vaccination among South Korean adult asthma patients: a nationwide

population-based cross-sectional study. *J Asthma* 2018; 55: 294–299.

- Kyung Y, Choi MH, Lee JS, et al. Influencing factors for influenza vaccination among South Korean adolescents with asthma based on a nationwide cross-sectional study. Int Arch Allergy Immunol 2020; 181: 434–445.
- 20. Cha SH, Paik JH, Lee MR, et al. Influenza vaccination coverage rate according to the pulmonary function of Korean adults aged 40 years and over: analysis of the fifth Korean National Health and Nutrition Examination Survey. *J Korean Med Sci* 2016; 31: 709–714.
- Kwon DS, Kim K and Park SM. Factors associated with influenza vaccination coverage among the elderly in South Korea: the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV). BMJ Open 2016; 6: e012618.
- 22. Lee Y-I, Jin Y and Nowak G. Motivating influenza vaccination among young adults: the effects of public service advertising message framing and text versus image support. *Soc Market Quarter* 2018; 24: 89–103.
- Kweon S, Kim Y, Jang MJ, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol 2014; 43: 69–77.
- Lee H, Shin SH, Gu S, *et al.* Racial differences in comorbidity profile among patients with chronic obstructive pulmonary disease. *BMC Med* 2018; 16: 178.
- Prevention and control of influenza pandemics and annual epidemics, https://apps.who.int/gb/ archive/pdf_files/WHA56/ea56r19.pdf (accessed 29 July 2022).
- 26. Zheng J, Chen F, Wu K, *et al.* Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients. *PLoS Negl Trop Dis* 2021; 15: e0009997.
- Yue H, Zhang M, Xing L, *et al.* The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. *f Med Virol* 2020; 92: 2870–2873.
- Bigaj J, Czaicki N and Zielonka TM. Factors affecting influenza vaccination rate in adults with asthma. Adv Exp Med Biol 2020; 1279: 101–111.
- 29. Guthrie JL, Fisman D and Gardy JL. Self-rated health and reasons for non-vaccination against

seasonal influenza in Canadian adults with asthma. *PLoS ONE* 2017; 12: e0172117.

- Yun JW, Noh JY, Song JY, et al. The Korean influenza national immunization program: history and present status. *Infect Chemother* 2017; 49: 247–254
- Dratva J, Wagner A, Zysset A, et al. To vaccinate or not to vaccinate – this is the question among Swiss University Students. Int J Environ Res Public Health 2021; 18: 9210.
- Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. *Allergy* 2007; 62: 591–604.
- 33. Mazurek JM, White GE, Moorman JE, *et al.* Influenza vaccination among persons with workrelated asthma. *Am J Prev Med* 2014; 47: 203–211.

- Mertz D, Kim TH, Johnstone J, *et al.* Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. *BMJ* 2013; 347: f5061.
- 35. Dhindsa DS, Khambhati J, Schultz WM, *et al.* Marital status and outcomes in patients with cardiovascular disease. *Trends Cardiovasc Med* 2020; 30: 215–220.
- 36. Yang B, Han K, Kim SH, et al. Being underweight increases the risk of non-cystic fibrosis bronchiectasis in the young population: a nationwide population-based study. *Nutrients* 2021; 13: 3206.
- Mendenhall E, Kohrt BA, Norris SA, et al. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. *Lancet* 2017; 389: 951–963.

Visit SAGE journals online journals.sagepub.com/ home/taj

SAGE journals